Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Metabolic Dysfunction-Associated Steatotic Liver Disease and Extrahepatic Cancers.

Created on 04 Nov 2026

Authors

Shiyu Peng, Zhui Ke, Han Ding, Xinyu Wang, Huiling Cao, Yuzhu Song, Yingying Nie, Yang Zhao, Jianni Qi, Qiang Zhu

Published in

British journal of hospital medicine (London, England : 2005). Volume 87. Issue 10. Pages 50779. Oct 15, 2026.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, and its high prevalence underscores the central role of metabolic dysregulation in its pathogenesis. Recent epidemiological studies have shown that MASLD is associated not only with hepatocellular carcinoma but also with an increased risk of several extrahepatic malignancies, including esophageal, gastric, colorectal, pancreatic, thyroid, breast, endometrial, renal, and prostate cancers. This review summarizes the emerging epidemiological links between MASLD and these extrahepatic cancers and discusses the biological mechanisms that may underlie these associations. We aim to describe both shared and organ-specific pathogenic pathways, highlight the importance of viewing MASLD as a systemic metabolic disorder in cancer prevention and clinical management, and outline future research directions from both conceptual and clinical perspectives. Future efforts should focus on biomarker development, multidisciplinary collaboration, and interventions targeting metabolic pathways.

PMID:
42980116
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement